NEURONETICS INC
Neuronetics Inc (ticker STIM) is a medical‑device company that develops and commercialises non‑invasive neurostimulation systems. Its flagship product, the NeuroStar Transcranial Magnetic Stimulation (TMS) System, is used primarily to treat major depressive disorder and related indications. The company earns revenue from device sales, clinical consumables, service contracts, training and, in some markets, clinic partnerships or leasing arrangements. With a market capitalisation of roughly $190.4m, Neuronetics is a small‑cap healthcare business: potential upside includes broader clinical adoption, expanded regulatory approvals and improved reimbursement, while risks include limited product diversification, competitive neuromodulation technologies, reimbursement uncertainty and the regulatory and commercial hurdles common to medical‑device firms. Investors should note small‑cap volatility and that past performance does not predict future returns. This content is general educational information only and not personal financial advice; suitability depends on an investor’s objectives and risk tolerance and you may wish to seek independent advice.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Neuronetics' stock with a target price of $7, indicating growth potential.
Financial Health
Neuronetics is performing well with solid revenue and profit margins, indicating healthy business operations.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring STIM
Injectable Drug Innovation Opportunities 2025
The FDA's approval of an at-home injectable version of Eisai and Biogen's Alzheimer's drug, Leqembi, simplifies treatment for patients and caregivers. This development highlights a growing trend toward patient-centric care, creating investment opportunities in companies that specialize in innovative drug delivery systems and at-home therapeutic technologies.
Published: August 31, 2025
Explore BasketPharma's Renewed Focus On Mental Health
AbbVie's potential $1 billion acquisition of Gilgamesh Pharmaceuticals signals a major strategic investment in the mental health sector. This move is expected to increase M&A interest and valuations for other biotech firms developing innovative psychiatric therapies.
Published: July 31, 2025
Explore BasketEmployee Mental Health As A Benefit
Discover companies transforming workplace wellness through innovative mental health solutions. These carefully selected stocks represent businesses helping corporations attract and retain talent by offering digital therapy, virtual counseling, and wellness technologies as employee benefits.
Published: June 17, 2025
Explore BasketImmersive Rehab & VR Therapy
Virtual and augmented reality are transforming healthcare with innovative digital treatments for physical and psychological healing. These carefully selected companies are at the forefront of creating immersive technologies that offer effective alternatives to traditional therapies, poised to benefit from growing clinical acceptance.
Published: June 17, 2025
Explore BasketBrain-Computer Interface
This collection features pioneering companies creating revolutionary pathways between the human brain and machines. These carefully selected stocks represent the cutting edge of neural technology, with potential to transform healthcare and computing through innovative brain signal interpretation.
Published: June 17, 2025
Explore BasketRest & Recharge
Tap into the booming wellness economy with companies revolutionizing how we sleep and relax. These carefully selected stocks represent innovative leaders in sleep technology, relaxation services, and wellness solutions that are responding to our growing desire for better rest and recovery.
Published: June 17, 2025
Explore BasketMental Wellness Portfolio
Invest in the future of mental healthcare. These carefully selected companies are leveraging technology to make mental health treatment more accessible, personalized, and effective, creating significant growth opportunities in an expanding market.
Published: June 17, 2025
Explore BasketMind & Spirit
Invest in companies transforming mental healthcare through innovative treatments and technologies. These carefully selected stocks represent leaders in psychedelic therapeutics, telehealth platforms, and neurological treatments addressing the growing global demand for mental wellness solutions.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Adoption & Growth
Broader clinical adoption and better reimbursement could lift sales, though uptake varies by region and payer coverage and performance can differ.
Innovation Programme
Ongoing clinical studies aim to expand indications and improve outcomes; technical progress and regulatory approvals will shape future prospects.
Market & Competition
Competes with other neuromodulation technologies and pharmacological treatments; reimbursement and competitor advances are important risks to monitor.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Abbott Laboratories
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
Agilent Technologies Inc.
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Life Sciences and Diagnostics Markets segment comprises seven areas of activity. It offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. Agilent CrossLab segment offers a services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to enhance customer outcomes. Applied Markets segment offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products.
Align Technology Inc.
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
